BioMelbourne Network Progressing BioIndustry

• Home
• About Us
• Events
• Grants & Awards
• News & Opinion
• Membership
• VicBioPortal
• Resource Library
• Contact

4th March - • Appointment of industry leader to emerging company• Growing team to drive and fast-track global activities• Innovative telomerase technology set for roll out in US markets in 2014 Sienna Cancer Diagnostics has appointed Matthew Hoskin as Chief Operating Officer in a move which strengthens the company’s capacity as it progresses commercialisation of its innovative technology for ... read more…

3rd March - Applications are now open for the 2014 L’Oréal Australia & New Zealand For Women in Science Fellowships We’re offering three AU$25,000 Fellowships for outstanding young female scientists through the highly competitive For Women in Science Fellowship program. The Fellowships will be awarded to three Australian or New Zealand women who have shown scientific excellence in their career... read more…

3rd March - Australian drug delivery technology company Phosphagenics Limited (ASX:POH; OTCQX:PPGNY) has appointed biotech industry veterans Mr Lawrence Gozlan, Mr Nathan Drona and Dr Geert Cauwenbergh as non-executive directors, with Mr Gozlan assuming the role of Chairman of the Board on an interim basis.   Mr Stuart James, Dr Sandra Webb, Mr Don Clarke and Mr Jonathan Addison have retired fr... read more…

24th February - Melbourne, Australia, 24th February 2014- Cancer Therapeutics CRC (CTx) is pleased to announce that the Cooperative Research Centres (CRC) Program has agreed to continue their funding for a further six years. The application, submitted in June 2013, highlighted both the success of CTx since its formation in July 2007 as well as the plans to build on that success.  The focus of t... read more…

24th February -  Axiron® launched by Eli Lilly in Germany  Testosterone therapy market in Germany is the second largest outside the US Acrux (ASX: ACR) today confirmed that Axiron® has now launched in Germany for testosterone replacement therapy in men for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). Germany is the second largest testost... read more…

21st February - Dr Tania Obranovich has joined the Watermark Melbourne office as Special Counsel. Tania practices as both a patent attorney and solicitor, specialising exclusively in biotechnology. She brings to Watermark the experience obtained in pursuing molecular and cellular immunology research to the post-doctoral level, as well as 20 years experience as an attorney with another national... read more…

21st February - The Australian Government will create three new Cooperative Research Centres (CRCs) and extend four existing CRCs to drive research that will deliver practical benefits to industry and the community in fields including manufacturing, agriculture, health care and data security. Announcing almost $186 million in funding, Minister for Industry Ian Macfarlane said CRCs bring togeth... read more…

20th February - · World first offering of a telomerase-based cancer diagnostic for bladder cancer · Cost-effective non-invasive urine-based test for key biomarker · Bladder cancer the fifth most common cancer in USA, but most expensive to treat Melbourne-based biotech firm Sienna Cancer Diagnostics has been awarded a Federal Government grant to commercialise its innovative technology for us... read more…

6th February - As part of the Victorian International Engagement Strategy the Victorian Government has established the Hamer Scholarships, a language and cultural immersion program designed to build the Asia-engagement capabilities of Victorians and help strengthen cultural awareness between Victoria and Asia. The program provides scholarships for Victorians each year to undertake intensive la... read more…

5th February - • Phase 2 trial met its primary endpoint, reduced pain in postherpetic neuralgia (PHN) versus placebo• Significant patient response to EMA401 treatment and drop in pain intensity compared with placebo, meeting a key secondary endpoint • First published demonstration of the therapeutic potential of angiotensin II type 2 (AT2) receptor antagonists• EMA401 identified as a possible ... read more…

3rd February - Global business communications consultancy, College Group (including leading brands College Hill, The College, College Public Policy, Policy Action, Green Issues Communique, Stockheim Media and Instinctif) announces that it is today rebranding and unifying its business operations under one single brand – Instinctif Partners.  This move sees all its operations – 20 wholly owned of... read more…

28th January - • Hormone replacement therapy (HRT) a large and growing therapeutic segment• Opportunity for IDT to acquire a HRT product application in the mid stages of FDA review• Good fit to IDT facilities and capabilities• Attractive commercial terms IDT Australia Limited (ASX:IDT) has secured an exclusive option agreement with Perrigo Company plc (Perrigo) to evaluate an acquisition of P... read more…

21st January, 2014• Novartis has launcheda diclofenac formulation under the product name Voveran®TPM gel in the Indian market• Themis’ launch of its diclofenac product Instanac® TPM gel in the Indian market will occur imminently Drug delivery technology company Phosphagenics Limited (ASX:POH; OTCQX:PPGNY) advises that Novartis has launched a topical diclofenac gel that has been formulated with... read more…

18th January - • Study shows ABRAXANE plus gemcitabine combination therapy further extends overall survival benefit • First Phase III trial in metastatic pancreatic cancer to report three year survival rates1• New standard of care for patients with metastatic pancreatic cancer A leading breast cancer drug, ABRAXANE® (nanoparticle albumin-bound paclitaxel), has been shown to extend overall sur... read more…

7th January 2014: Analysis from leading healthcare fund manager BioScience Managers has highlighted the outstanding year for biotech stocks on the ASX in 2013 with an average gain of 53.6%* across the sector. These findings compare with the All Ordinaries index that increased by 14.7% over 2013 and the S&P/ASX 200 Health Care Index which increased 23.5% for the calendar year and 79.9% over the... read more…

7th January, 2014  Agreement to Distribute Oncotype DX® in Australia and New Zealand Oncotype DX now regarded as standard-of-care for early stage breast cancer treatment planning in the US since becoming available there in 2004 Australian women will potentially have greater access to the only genomic test validated to predict whether patients with early-stage invasive breast cancer would... read more…

16th December - Australia’s underestimated resource: women doing business globally In 2012, the University of Melbourne and Women in Global Business commenced a five year longitudinal study on the motivations and barriers experienced by Australia’s businesswomen as they engage with international markets. The first year results were a revelation in this rarely studied group of women contributi... read more…

12th December 2013 - Brisbane.   Provides infrastructure for CardioCel® production Provides an instant, highly skilled and experienced production team Accelerates scale up manufacturing of CardioCel® for global markets Admedus, formerly Allied Healthcare Group (ASX: AHZ) today announced that it has signed a share purchase agreement to acquire an established manufacturing site from Genzyme ... read more…

12 December 2013 - • Hatchtech receives FDA agreement of its DeOvo Phase III study design via the Special Protocol Assessment (SPA) process allowing for the commencement of two pivotal studies in early 2014;• Additional Hatchtech patents allowed in Europe and Japan which further strengthens the commercial protection of DeOvo internationally. Hatchtech today announced that it has received fina... read more…

12 December -   • Australian scientists developed new feed inclusion supplement that reduced antibiotic use on-farm• MMA selling Udder-Mate® in Australia and New Zealand Australian drug delivery technology company Phosphagenics Limited (ASX:POH; OTCQX:PPGNY), with its licensee Mastitis Management Australia (MMA), today announced that MMA’s Udder-Mate® feed inclusion technology, which includes... read more…